Table 1 Clinical characteristics of patients administered with remimazolam (RMZ).
Number of patients | 20 |
Number of measurements | 60 |
Sex (male/female) | 12/8 |
Age (years) | 71.7 (42.2–88.6) |
Body weight (kg) | 60.4 (44.5–77.1) |
Body mass index (kg/m2) | 23.1 (18.1–28.0) |
Serum creatinine (mg/dL) | 0.81 (0.50–1.28) |
Creatinine clearance (mL/min) | 72.6 (41.6–115.6) |
Estimated glomerular filtration rate (mL/min/1.73 m2) | 70.1 (45.3–89.7) |
Aspartate amino transferase (IU/L) | 21 (15–48) |
Alanine aminotransferase (IU/L) | 21 (8–57) |
Plasma concentration of RMZ (ng/mL) | 1159 (745.4–2471.3) |
Plasma concentration of CNS7054 (ng/mL) | 485 (103–1568.9) |
Bispectral index (BIS) | 53 (36–83) |
The time to loss of consciousness after starting the infusion (min) | 1.71 (1.20–3.00) |
